Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL27832667 | 0.94 | ALDH1A3 (0.41) | ALDH1A3CHRNB2CHRNA4KMT2AACACB | |
| SCHEMBL15006226 | 0.83 | CHRNB2 (0.39) | CHRNB2CHRNA4KMT2ACHRNB1CHRNB4 | |
| SCHEMBL12147787 | 0.81 | RXRA (0.41) | CHRNB2CHRNA4KMT2ACHRNB1CHRNB4 | |
| SCHEMBL1000603 | 0.78 | NOS3 (0.46) | ALDH1A3KMT2AACACBPARP10 | |
| SCHEMBL17662611 | 0.78 | KMT2A (0.42) | CHRNB2CHRNA4KMT2ACHRNB1CHRNB4 | |
| SCHEMBL11951648 | 0.77 | KDM4E (0.40) | ALDH1A3KMT2AACACBPARP10 | |
| SCHEMBL12924083 | 0.77 | ALDH1A3 (0.39) | ALDH1A3KMT2AACACBPARP10 | |
| SCHEMBL17420414 | 0.77 | ALDH1A3 (0.39) | ALDH1A3KMT2AACACBPARP10 | |
| Hydrochloric Acid SCHEMBL710140 | 0.77 | NOS3 (0.45) | ALDH1A3KMT2AACACBPARP10 | |
| SCHEMBL4741323 | 0.77 | SYK (0.43) | ALDH1A3CHRNB2CHRNA4KMT2AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118946556-A | DGK targeting compounds and uses thereof | 阿维纳斯运营公司 | 2024-11-12 | — | — | CN | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3728216-B1 | PYRAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| EP-3728240-B1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-29 | — | — | EP | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-5563159-A | Dithiocarbonimide derivatives useful as acaricidal, fungicidal, and insecticidal agents | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-10-08 | — | — | US | disclosed |
| US-4923504-A | 2-(2-Imidazolin-2-yl)pyridines and quinolines, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| US-4798619-A | 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents | AMERICAN CYANAMID CO. (US) | 1989-01-17 | — | — | US | disclosed |
| US-4638068-A | 2-(2-imidazolin-2-yl)-pyridines and quinolines, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0095104-B1 | PROCESS FOR THE PREPARATION OF PYRIDYL AND QUINOLYL IMIDAZOLINONES | AMERICAN CYANAMID COMPANY (US) | 1986-12-17 | — | — | EP | disclosed |
| US-4474962-A | CYCLIZATION, ONE STEP | AMERICAN CYANAMID COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| WO-1983004252-A1 | PROCESS FOR THE PREPARATION OF PYRIDYL AND QUINOLYL IMIDAZOLINONES | AMERICAN CYANAMID COMPANY (US) | 1983-12-08 | — | — | WO | disclosed |
| EP-0095104-A2 | Process for the preparation of pyridyl and quinolyl imidazolinones | AMERICAN CYANAMID COMPANY (US) | 1983-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | ALDH1A3 1397/4885CHRNB2 4786/4885CHRNA4 4856/4885 |
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | ALDH1A3 1156/4885CHRNB2 657/4885CHRNA4 163/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | ALDH1A3 3236/4885CHRNB2 4840/4885CHRNA4 4856/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | ALDH1A3 920/4885CHRNB2 4870/4885CHRNA4 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.